- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 31.01.2025 | 214 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.01.2025
Aktien
1 CA6699882065 Nu E Power Corp.
2... ► Artikel lesen | |
| 10.12.24 | Participation in warrant exercise by Curasight management | 2 | Cision News | ||
| 10.12.24 | Curasight A/S announces outcome of warrant exercise | 2 | Cision News | ||
| 02.12.24 | CURASIGHT: SEB maintain valuation range midpoint at DKK 54 per share | 5 | Cision News | ||
| 02.12.24 | CURASIGHT: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 | 3 | Cision News | ||
| 28.11.24 | Spotlight Stock Market: Market Notice 251/24- Last day of trading in Curasight A/S's subscription option CURAS TO 2 | 1 | Cision News | ||
| 26.11.24 | Curasight CEO reflects on a Q3 with strong progress | 1 | Cision News | ||
| 22.11.24 | Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] | 1 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 21.11.24 | CURASIGHT: The exercise period for warrants of series TO2 commences today | 1 | Cision News | ||
| 21.11.24 | CURASIGHT: Interim report Q3 2024 | 4 | Cision News | ||
| 20.11.24 | CURASIGHT: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share | 5 | Cision News | ||
| 15.11.24 | Curasight announces brain cancer as initial target for uTREAT | 1 | Cision News | ||
| 14.11.24 | Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference | 2 | Cision News | ||
| 13.11.24 | Curasight announces international patent application for uTREAT® to broaden IP protection | 1 | Cision News | ||
| 11.11.24 | Curasight will present at the BioStock Life Science Summit, November 21 | 1 | Cision News | ||
| 11.11.24 | Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 | 1 | Cision News | ||
| 08.11.24 | CURASIGHT: Full phase II results of uPAR-PET in glioblastoma published | 1 | Cision News | ||
| 08.11.24 | Curasight to present at Dansk Aktionærforening InvestorDagen | 1 | Cision News | ||
| 07.11.24 | CURASIGHT: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer | 4 | Cision News | ||
| 22.10.24 | Curasight well-placed in hot radiopharma sector | 1 | Cision News |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,50 | +0,54 % | Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky Sells 82,056 Shares | ||
| IMMUNOVANT | 21,740 | -1,50 % | Here's Why Immunovant, Inc. (IMVT) Will Double in 2025 | ||
| RECURSION PHARMACEUTICALS | 7,240 | -5,85 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| IMMUNOME | 11,030 | +4,95 % | Immunome Inc. - 8-K, Current Report | ||
| MAZE THERAPEUTICS | 15,950 | 0,00 % | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 37,500 | +0,73 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | ||
| AVIDITY BIOSCIENCES | 32,930 | +0,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| EVOTEC | 8,650 | +0,82 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
| JANUX THERAPEUTICS | 43,480 | -2,92 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 53,76 | +3,90 % | A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts | ||
| ARS PHARMACEUTICALS | 13,020 | -8,89 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| 89BIO | 9,600 | -0,52 % | 89bio, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 14,220 | +0,57 % | Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next? | ||
| BIONTECH | 118,90 | -0,34 % | JPMORGAN stuft Biontech auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Biontech von 122 auf 120 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Ihre aktualisierten Schätzungen für die... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,400 | +0,87 % | Vir Biotechnology, Inc. - 8-K, Current Report |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,225 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.
